1. Home
  2. EPSM vs CTXR Comparison

EPSM vs CTXR Comparison

Compare EPSM & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Epsium Enterprise Limited Ordinary Shares

EPSM

Epsium Enterprise Limited Ordinary Shares

N/A

Current Price

$0.83

Market Cap

12.3M

Sector

N/A

ML Signal

N/A

Logo Citius Pharmaceuticals Inc.

CTXR

Citius Pharmaceuticals Inc.

N/A

Current Price

$0.56

Market Cap

13.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
EPSM
CTXR
Founded
2010
2007
Country
China
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.3M
13.4M
IPO Year
2021
2010

Fundamental Metrics

Financial Performance
Metric
EPSM
CTXR
Price
$0.83
$0.56
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
23.8K
★ 262.6K
Earning Date
11-24-2026
12-22-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 43.38
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$104.18
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.77
$0.37
52 Week High
$10.19
$1.54

Technical Indicators

Market Signals
Indicator
EPSM
CTXR
Relative Strength Index (RSI) 36.89 58.03
Support Level $0.83 $0.55
Resistance Level $1.64 $0.61
Average True Range (ATR) 0.08 0.05
MACD -0.00 0.02
Stochastic Oscillator 32.76 77.05

Price Performance

Historical Comparison
EPSM
CTXR

About EPSM Epsium Enterprise Limited Ordinary Shares

Epsium Enterprise Ltd is a holding company and conducts business through its subsidiaries. It is engaged in import trading and wholesale selling of beverages in Macau. The company imports and sells a range of beverages, alcoholic beverages, and a small quantity of tea and fruit juice. The alcoholic beverages it sells include Chinese liquor, French cognac, Scottish whiskey, fine wine, Champagne, and other miscellaneous beverage alcohols.

About CTXR Citius Pharmaceuticals Inc.

Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.

Share on Social Networks: